Curative Biotechnology (NASDAQ: CBIO) Advances Clinical Supply Manufacturing for Metformin Ophthalmic Therapy

April 15, 2026

Key Developments Curative Biotechnology (NASDAQ: CBIO) has announced a strategic manufacturing agreement with Sterling Pharmaceutical Services to produce the clinical supply of its metformin topical ophthalmic therapy. This collaboration marks a significant advancement in the company’s ophthalmology platform as it moves closer to initiating its first-in-human clinical study. The partnership with Sterling Pharmaceutical Services supports the production scale-up and ensures the availability of the necessary clinical materials, highlighting Curative Biotechnology’s…

Read More >>